Chemotherapy and novel therapeutics before radical prostatectomy for high-risk clinically localized prostate cancer

Urologic Oncology: Seminars and Original Investigations

Volumn 33, Issue 5, 2015, Pages 217-225

  Cha, Eugene K ^a   Eastham, James A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Chemotherapy; High risk prostate cancer; Neoadjuvant therapy; Novel therapeutics

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; BUSERELIN ACETATE; CARBOPLATIN; CLUSTERIN; CUSTIRSEN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTRAMUSTINE; GEFITINIB; GOSERELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; IMATINIB; IPILIMUMAB; LEUPRORELIN; NILUTAMIDE; PACLITAXEL; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RITUXIMAB; SIPULEUCEL T; SUNITINIB; VASCULOTROPIN RECEPTOR;

ANDROGEN DEPRIVATION THERAPY; ANGIOGENESIS; CANCER ADJUVANT THERAPY; DRUG EFFICACY; DRUG SAFETY; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; MALE; MULTICENTER STUDY (TOPIC); OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROSTATECTOMY; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMIC THERAPY; DISEASE COURSE; NEOADJUVANT THERAPY; PATHOLOGY; PROCEDURES; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; HUMANS; MALE; NEOADJUVANT THERAPY; PROSTATECTOMY; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84929296262     PISSN: 10781439     EISSN: 18732496     Source Type: Journal    
DOI: 10.1016/j.urolonc.2014.11.020     Document Type: Review

References (48)

1. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014, 64:9-29.
2. Mohler J.L., Kantoff P.W., Armstrong A.J., Bahnson R.R., Cohen M., D'Amico A.V., et al. Prostate cancer, version 2.2014. J Natl Compr Canc Netw 2014, 12:686-718.
3. Yossepowitch O., Eggener S.E., Bianco F.J., Carver B.S., Serio A., Scardino P.T., et al. Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods. J Urol 2007, 178:493-499. [discussion 9].
4. Kane C.J., Presti J.C., Amling C.L., Aronson W.J., Terris M.K., Freedland S.J., et al. Changing nature of high risk patients undergoing radical prostatectomy. J Urol 2007, 177:113-117.
5. Bolla M., Collette L., Blank L., Warde P., Dubois J.B., Mirimanoff R.O., et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360:103-106.
6. Yee D.S., Lowrance W.T., Eastham J.A., Maschino A.C., Cronin A.M., Rabbani F. Long-term follow-up of 3-month neoadjuvant hormone therapy before radical prostatectomy in a randomized trial. BJU Int 2010, 105:185-190.
7. Soloway M.S., Pareek K., Sharifi R., Wajsman Z., McLeod D., Wood D.P., et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxMo prostate cancer: 5-year results. J Urol 2002, 167:112-116.
8. Klotz L.H., Goldenberg S.L., Jewett M.A., Fradet Y., Nam R., Barkin J., et al. Long-term followup of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003, 170:791-794.
9. von Minckwitz G., Untch M., Blohmer J.U., Costa S.D., Eidtmann H., Fasching P.A., et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 2012, 30:1796-1804.
10. Grossman H.B., Natale R.B., Tangen C.M., Speights V.O., Vogelzang N.J., Trump D.L., et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med 2003, 349:859-866.
11. Rastogi P., Anderson S.J., Bear H.D., Geyer C.E., Kahlenberg M.S., Robidoux A., et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008, 26:778-785.
12. International Collaboration of Trialists; Medical Research Council Advanced Bladder Cancer Working Party; European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group; Australian Bladder Cancer Study Group; National Cancer Institute of Canada Clinical Trials Group, et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J Clin Oncol 2011;29:2171-2177.
13. Sauer R., Becker H., Hohenberger W., Rodel C., Wittekind C., Fietkau R., et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004, 351:1731-1740.
14. van Hagen P., Hulshof M.C., van Lanschot J.J., Steyerberg E.W., van Berge Henegouwen M.I., Wijnhoven B.P., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012, 366:2074-2084.
15. Petrylak D.P., Tangen C.M., Hussain M.H., Lara P.N., Jones J.A., Taplin M.E., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004, 351:1513-1520.
16. Tannock I.F., de Wit R., Berry W.R., Horti J., Pluzanska A., Chi K.N., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004, 351:1502-1512.
17. de Bono J.S., Oudard S., Ozguroglu M., Hansen S., Machiels J.P., Kocak I., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376:1147-1154.
18. Dreicer R., Magi-Galluzzi C., Zhou M., Rothaermel J., Reuther A., Ulchaker J., et al. Phase II trial of neoadjuvant docetaxel before radical prostatectomy for locally advanced prostate cancer. Urology 2004, 63:1138-1142.
19. Magi-Galluzzi C., Zhou M., Reuther A.M., Dreicer R., Klein E.A. Neoadjuvant docetaxel treatment for locally advanced prostate cancer: a clinicopathologic study. Cancer 2007, 110:1248-1254.
20. Febbo P.G., Richie J.P., George D.J., Loda M., Manola J., Shankar S., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 2005, 11:5233-5240.
21. Friedman J., Dunn R.L., Wood D., Vaishampayan U., Wu A., Bradley D., et al. Neoadjuvant docetaxel and capecitabine in patients with high risk prostate cancer. J Urol 2008, 179:911-915. [discussion 5-6].
22. Shepard D.R., Dreicer R., Garcia J., Elson P., Magi-Galluzzi C., Raghavan D., et al. Phase II trial of neoadjuvant nab-paclitaxel in high risk patients with prostate cancer undergoing radical prostatectomy. J Urol 2009, 181:1672-1677. [discussion 7].
23. Garzotto M., Higano C.S., O'Brien C., Rademacher B.L., Janeba N., Fazli L., et al. Phase 1/2 study of preoperative docetaxel and mitoxantrone for high-risk prostate cancer. Cancer 2010, 116:1699-1708.
24. Pettaway C.A., Pisters L.L., Troncoso P., Slaton J., Finn L., Kamoi K., et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 2000, 18:1050-1057.
25. Clark P.E., Peereboom D.M., Dreicer R., Levin H.S., Clark S.B., Klein E.A. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 2001, 57:281-285.
26. Konety B.R., Eastham J.A., Reuter V.E., Scardino P.T., Donat S.M., Dalbagni G., et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 2004, 171:709-713.
27. Silberstein J.L., Poon S.A., Sjoberg D.D., Maschino A.C., Vickers A.J., Bernie A., et al. Long term oncologic outcomes of a Phase II trial of neoadjuvant chemohormonal therapy followed by radical prostatectomy for patients with clinically localized, high-risk prostate cancer. BJU Int 2014.
28. Prayer-Galetti T., Sacco E., Pagano F., Gardiman M., Cisternino A., Betto G., et al. Long-term follow-up of a neoadjuvant chemohormonal taxane-based phase II trial before radical prostatectomy in patients with non-metastatic high-risk prostate cancer. BJU Int 2007, 100:274-280.
29. Chi K.N., Chin J.L., Winquist E., Klotz L., Saad F., Gleave M.E. Multicenter phase II study of combined neoadjuvant docetaxel and hormone therapy before radical prostatectomy for patients with high risk localized prostate cancer. J Urol 2008, 180:565-570.
30. Sella A., Zisman A., Kovel S., Yarom N., Leibovici D., Lindner A. Neoadjuvant chemohormonal therapy in poor-prognosis localized prostate cancer. Urology 2008, 71:323-327.
31. Mellado B., Font A., Alcaraz A., Aparicio L.A., Veiga F.J., Areal J., et al. Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. Br J Cancer 2009, 101:1248-1252.
32. Womble P.R., VanVeldhuizen P.J., Nisbet A.A., Reed G.A., Thrasher J.B., Holzbeierlein J.M. A phase II clinical trial of neoadjuvant ketoconazole and docetaxel chemotherapy before radical prostatectomy in high risk patients. J Urol 2011, 186:882-887.
33. Narita S., Tsuchiya N., Kumazawa T., Maita S., Numakura K., Obara T., et al. Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk localized prostate cancer. World J Surg Oncol 2012, 10:1.
34. Eastham J.A., Kelly W.K., Grossfeld G.D., Small E.J. Cancer, Leukemia Group B. Cancer and Leukemia Group B (CALGB) 90203: a randomized phase 3 study of radical prostatectomy alone versus estramustine and docetaxel before radical prostatectomy for patients with high-risk localized disease. Urology 2003, 62(Suppl. 1):55-62.
35. Cancer and Leukemia Group B. Surgery with or without docetaxel and leuprolide or goserelin in treating patients with high-risk localized prostate cancer [ClinicalTrials.gov identifier ]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov.
36. Ross R.W., Galsky M.D., Febbo P., Barry M., Richie J.P., Xie W., et al. Phase 2 study of neoadjuvant docetaxel plus bevacizumab in patients with high-risk localized prostate cancer: a Prostate Cancer Clinical Trials Consortium trial. Cancer 2012, 118:4777-4784.
37. Zurita A.J., Ward J.F., Araujo J.C., Pettaway C.A., Dieringer P., Wang X., et al. Neoadjuvant trial of sunitinib malate and androgen ablation (ADT) in patients with localized prostate cancer (PCa) at high risk for recurrence. J Clin Oncol 2011, 29(suppl.):7. [abstr 143].
38. Vuky J., Porter C., Isacson C., Vaughan M., Kozlowski P., Picozzi V., et al. Phase II trial of neoadjuvant docetaxel and gefitinib followed by radical prostatectomy in patients with high-risk, locally advanced prostate cancer. Cancer 2009, 115:784-791.
39. Febbo P.G., Thorner A., Rubin M.A., Loda M., Kantoff P.W., Oh W.K., et al. Application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006, 12:152-158.
40. Mathew P., Pisters L.L., Wood C.G., Papadopoulos J.N., Williams D.L., Thall P.F., et al. Neoadjuvant platelet derived growth factor receptor inhibitor therapy combined with docetaxel and androgen ablation for high risk localized prostate cancer. J Urol 2009, 181:81-87.
41. Chi K.N., Eisenhauer E., Fazli L., Jones E.C., Goldenberg S.L., Powers J., et al. A phase I pharmacokinetic and pharmacodynamic study of OGX-011, a 2'-methoxyethyl antisense oligonucleotide to clusterin, in patients with localized prostate cancer. J Natl Cancer Inst 2005, 97:1287-1296.
42. University of British Columbia. Study of OGX-011 given prior to radical prostatectomy in patients with localized prostate cancer. [ClinicalTrials.gov identifier ]. US National Institutes of Health, ClinicalTrials.gov [online]. http://www.clinicaltrials.gov.
43. Kantoff P.W., Higano C.S., Shore N.D., Berger E.R., Small E.J., Penson D.F., et al. Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 2010, 363:411-422.
44. Fong L., Weinberg V.K., Chan S.E., Corman J.M., Amling C.L., Stephenson R.A., et al. Neoadjuvant sipuleucel-T in localized prostate cancer: Effects on immune cells within the prostate tumor microenvironment. J Clin Oncol 2012, (suppl.):30. [abstr 2564].
45. Flaig T.W., Tangen C.M., Hussain M.H., Stadler W.M., Raghavan D., Crawford E.D., et al. Randomization reveals unexpected acute leukemias in Southwest Oncology Group prostate cancer trial. J Clin Oncol 2008, 26:1532-1536.
46. Layton J.L., Plette A.M., Renzulli J.F., Miller E.B., Safran H., Mega A.E. The impact of neoadjuvant weekly ixabepilone for high-risk prostate cancer: a phase I/II clinical trial. J Clin Oncol 2012, 30(suppl 5). [abstr 158].
47. Hussain M., Smith D.C., El-Rayes B.F., Du W., Vaishampayan U., Fontana J., et al. Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locallyadvanced prostate cancer. Urology 2003, 61:774-780.
48. Vuky J., Corman J.M., Porter C., Olgac S., Auerbach E., Dahl K. Phase II trial of neoadjuvant docetaxel and CG1940/CG8711 followed by radical prostatectomy in patients with high-risk clinically localized prostate cancer. Oncologist 2013, 18:687-688.